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Grzegorz Wladyslaw Basak,1,2 Ewa Carrier1Recent years have brought significant breakthroughs in the understanding of tumor biology, related to dis-
covery of cancer stem cells (CSCs) in acute myelogenous leukemia as well as in a number of solid tumors.
This finding revealed that not all tumor cells are able to divide indefinitely, and that the bulk of tumor cells
are expanded because of divisions and differentiation of CSC fraction. Although the CSCs identified in acute
leukemia have a phenotype of early hematopoietic progenitors, it seems that CSCs in multiple myeloma (MM)
may resemble the memory B cell fraction. Previous studies in patients with MM have documented the exis-
tence of cells without plasma cell characteristics expressing MM-type immunoglobulin genes—so-called ‘‘clo-
notypic’’ B cells. These cells have been characterized functionally and phenotypically as chemoresistant
recirculating B cells. They have been found to self-renew and to be capable of initiating MM growth in immu-
nocompromised animals. Controversy exists as to whether these cells truly belong to an MM clone, how-
ever; they may represent only the remaining clones of premalignant B cells. The identification of MM stem
cells responsible for the recurrence of MM is of primary importance in designing targeted therapies to def-
initely cure this disease. This article summarizes the current state of knowledge on these hypothetical ‘‘MM
stem cells.’’
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The cancer stem cell (CSC) hypothesis is based on
the assumption that tumors contain a cellular subcom-
ponent retaining key stem cell properties including,
but not limited to, potency of both self-renewal and
differentiation [1-3]. Actually, this is more than an
assumption, as there is clear experimental evidence
for the existence of CSCs in a proportion of tumors.
Historically, the investigation of acute myelogenous
leukemia (AML) in the early 1990s revealed that the
leukemic clone is organized hierarchically. Whereas
the majority of blast cells proliferate rapidly, the dis-
ease is maintained by relatively quiescent leukemic
stem cells (LSCs) [1,4,5]. Consequently, the quies-
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[2,6,7]. Since that time, it has been widely accepted
that only the elimination of CSCs (or LSCs) can cure
neoplastic diseases. Over the past 20 years, several in-
vestigators revisited the idea that different cancers may
originate in the CSC compartment [2]. There remains
very little evidence for the existence of CSCs in lym-
phoproliferative disorders, however. In contrast to
acute leukemias, in the majority of chronic lympho-
proliferative disorders, the neoplastic cell clone is
characterized by specific patterns of immunoglobulin
or T cell receptor genes, rearrangements, and muta-
tions. These events do not occur at the hematopoietic
stem cell (HSC) (level, and thus these neoplasms seem
to arise much later in the course of cell development.
In particular, the memory-type lymphocytes seem to
be likely candidates for malignant transformation in
chronic lymphoproliferative disorders, because (unlike
any other cells in the body) they share many functional
and molecular features with stem cells [8]. Thus, it is
highly likely that the CSCs in these disorders represent
rather differentiated cell fractions with stem cell prop-
erties.MULTIPLE MYELOMA
Multiple myeloma (MM) is a cancer of plasma cells
hallmarked by tumor cell tropism for bone marrow587
588 Biol Blood Marrow Transplant 16:587-594, 2010G. W. Basak and E. Carrier(BM) and the production of monoclonal immunoglob-
ulin detectable in serumand/or urine.Clinicalmanifes-
tations include anemia, lytic bone lesions, diffuse
osteoporosis, hypercalcemia, renal dysfunction, and in-
creased risk of infection. The first pathogenetic step in
the development of MM is the emergence of a limited
number of clonal plasma cells, clinically known as
monoclonal gammopathy of unknown significance
(MGUS). The progression to MM involves complex
events in both the progenitor cells and the BM micro-
environment [9,10].
Current therapeutic approaches to MM include
steroids, alkylating agents (eg, melphalan [Mel]),
immunomodulatory agents (eg, thalidomide, lenalido-
mide), and proteasome inhibitors (eg, bortezomib),
with or without stem cell transplantation (SCT) [11].
But, the median survival of patients with MM treated
with these agents is only about 3 years, with some im-
provement seen with high-dose therapy and stem cell
rescue. Allogeneic SCT (allo-SCT) provides the only
potential for cure, but this has been largely abandoned
because of highmortality rate [12]. These observations
suggest that someMM cells are not targeted efficiently
by current drug therapies. These cells may differ from
most plasma cells in terms of biology and phenotype
and may rebuild the population of MM clone, causing
disease relapse and ultimately death. These cells could
constitute the hypothetic MM stem cell fraction.
The existence of myeloma tumor stem cells was first
suggested by Park et al. [13] in 1971. These authors de-
scribed culture conditions in which murine myeloma
cells formed colonies and suggested that each of these
colonies comes from a single MM stem cell. Ham-
burger and Salmon [14] made a similar observation in
human MM cells and noted their very low plating
efficiency (0.001%-0.1%), positing that the rare cells
giving rise to colonies could be the hypothetical MM
stem cells. This observation was confirmed by other
studies showing a very low proliferative index of MM
plasma cells (only about 1%) [15].WhetherMMplasma
cells have the proliferative capacity required for the
initiation, maintenance, and progression of clinical
disease, is uncertain.CLONOTYPIC B CELLS
In the early 1990s, studies of the B cell repertoire in
the peripheral blood (PB) of MM patients led to the
observation that a proportion of circulating CD19 1
B lymphocytes is monoclonal [16]. These cells exclu-
sively expressmRNAof either thekappaor lambda light
chain, consistent with findings in corresponding MM
plasma cells [17].The IgHrearrangements in PBB cells
of MM patients, which are identical to those expressed
by the BM plasma cells, have been confirmed by Ig
fingerprint and allele-specific oligomer (ASO) poly-merase chain reaction (PCR) methods [18], and then
by reverse-transcription (RT)-PCR, single-cell
RT-PCR, in situ RT-PCR, and gene sequencing
methods [19-21]. These MM PB B cells have been
termed ‘‘clonotypic B cells,’’ because their association
withwith theMMclone seems undisputable.The num-
ber of clonotypic B cells was found to vary betweenMM
patients, constituting 66% of blood B cells on average
(range, 9% to 95%), with a mean absolute number of
0.15  109/L of blood [19].
Although these clonotypic B cells also have been
identified in BM and lymph nodes [22,23], themajority
of studies have been performed on PB clonotypic B
cells. The accumulated data suggest that clonotypic
B cells are a highly heterogenous cell fraction. Based
on their morphological characteristics, they appear as
either small or large B cells. The small cells resemble
normal B lymphocytes; they express CD45RO and
PCA-1, unlike normal B cells, but have only minor
expression of CD56 (moderate intensity) and high ex-
pression of CD38. On the other hand, the large B cells
coexpress CD19, CD20, CD10, CD45RO, CD11b,
plasma cell membrane glycoprotein-1 (PCA-l), and
a moderate level of CD56, and nearly half of them ex-
press a high level of CD38 [16,20,22,24,25]. The clo-
notypic B cells also appear to be highly heterogenous
in the expression of other molecules, including
CD27, CD62L, CXCR4, and CCR6 [25,26], but all
express CXCR5 [25] and CD11b [17]. They also do
not express CD34 antigen, which is characteristic of
the HSC fraction [20,27].
In contrast to previous studies, Matsui et al. [23]
divided MM BM cells into CD138-positive (plasma
cells) and CD138-negative (immature) fractions.
They documented clonogenic properties of the MM
CD138-negative fraction (including clonotypic
CD34-, CD191, and CD201 cells), but not
CD138-positive cells, which we discuss later. Clono-
typic B cells have been found to express cytoplasmic
Ig light chains; however, in a fraction of small cells,
a significant proportion exhibited a surface staining
pattern of light chains [24].
A number of studies have addressed the expression
of CD45 isoforms by clonotypic B cells, which may
reveal B lymphocyte differentiation status. Normal
mature B cells express a high density of CD45 mole-
cules, resting cells mainly express the CD45RA
isoform, and activated cells express the CD45R0
isoform; however, they gradually lose total CD45
expression, predominantly of the CD45R0 isoform,
during plasma cell differentiation. BM MM plasma
cells are characteristically CD45-low or -negative in
most cases. Most PB clonotypic B cells have been
shown to be CD45-high (CD45R01) [21,22,28]; how-
ever, some subpopulations have different patterns of
CD45 expression [16,22]. Clonotypic B cells also
have been identified in secondary lymphoid organs
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(primarily the CD45R0 isoform), suggesting their
most immature phenotype. Based on these observa-
tions, PB clonotypic B cells have been suggested to
constitute a population of continuously differentiating
MM cells from a late B cell stage through the early
plasma cell stages to an end-stage plasma cell [16,22],
which may migrate between peripheral blood and
both primary and secondary lymphoid organs [25]. If
the CD45-high (CD45R01) clonotypic B cells repre-
sent the proliferating fraction of MM, then the data on
expression of CD45 would seem to be consistent with
recent findings demonstrating high expression of
CD45 by a proliferative fraction of theMM clone [15].
According to one hypothesis, clonotypic B cells
originate in the peripheral lymphoid system and
migrate to the BM microenvironment to differentiate
into plasma cells [28]. The finding of CD11b beta 2-
integrin expression in clonotypic B cells, but not in
MM plasma cells, seems to confirm this hypothesis.
CD11b beta 2-integrin potentially could play a role
in the transendothelial migration of these cells to the
BM [17]. Another theory suggests that clonotypic B
cells may originate in the BM, enter the circulation
and metastasize to other skeletal or extraskeletal sites
[28]. The high expression of CXCR5 molecules could
influence their migration to secondary lymphoid
organs [25]. Moreover, clonotypic B lymphocytes
and MM plasma cells, but not normal B cells, have
been found to express receptor for hyaluronyan-medi-
ated motility (RHAMM) [29,30]. In contrast to plasma
cells, clonotypic B cells are able to actively migrate on
hyaluronyan, because of their active conformation of
RHAMM receptors. As one of the main constituents
of extracellular membranes, hyaluronyan could facili-
tate the migration of MM clonotypic B cells out of
BM [26]. The expression pattern of beta 1-integrin
chains clearly distinguishes abnormal MM B cells
from MM plasma cells and from normal B lympho-
cytes [31]. These observations indicated that the end-
stage plasma cells, in contrast to clonotypic B cells,
lack receptors that would support their invasion of
basement membranes and exit to extravascular spaces.CLONOTYPIC PRESWITCH B CELLS
The key stages of B lymphocyte development can
be tracked based on a unique pattern of immunoglob-
ulin genes that undergo irreversible changes, such as V
gene rearrangement, immunoglobulin heavy chain
class switching, and somatic hypermutations occurring
at germinal centers. Thus, the MM plasma cell clones
express IgG, IgA, IgD, IgM, or kappa or lambda light
chains exclusively, or, pathologically, do not secrete
immunoglobulins. In all cases, including IgM, the
immunoglobulin genes in MM plasma cells are hyper-mutated, with a consistent pattern of hypermutations
within the clone, which certifies their postgerminal
center character [32]. However, many studies have
documented the existence of cells expressing MM-
type Vh gene sequences (clonotypic), but linked to
different classes of Ig heavy-chain constant region
genes [33-36]. Clonotypic cells with different immu-
noglobulin classes, including preswitch (IgM) immu-
noglobulins, have been identified in some patients, as
have light-chain expressing MMs. Cells with different
classes of Ig heavy chains have been shown to have
identical patterns of hypermutations [35].
Preswitch (IgM1) clonotypic cells have been iden-
tified in the BM in most patients; however, their fre-
quency is very low, necessitating highly sensitive
diagnostic methods. Their frequency in PB is even
lower [34,36]. These cells do not seem to be mobilized
to PB during peripheral blood stem cell (PBSC) har-
vest; however, they have been found in cell prepara-
tions used for autologous SCT (auto-SCT) [33,36].
Interestingly, a fraction of patients exhibit persistent
expression of preswitch clonotypic transcripts in the
blood despite therapy, including high-dose chemo-
therapy with stem cell rescue, suggesting their drug
resistance [36]. The persistence of apparent drug-
resistant preswitch clonotypic isotypes has been asso-
ciated with reduced survival and more advanced
disease at the time of diagnosis [36]. Moreover, both
preswitched and postswitched cells from single
patients could be engrafted into mice. Recently, the is-
sue of preswitch (IgM1) clonotypic cells was finally
solved by Taylor et al. [37] using a specific clono-
typic-switch PCR. They hypothesized that if the
preswitch IgM1 clonotypic B cells replenish the
MM plasma cell pool, they must undergo several
rounds of class switch recombination (CSR), a process
identifiable in postswitch plasma cells as multiple IgH
switch junctions associated with single clonotypic IgH
V/D/J. Importantly, they could detect only a single
clonotypic switch fragment in all of the MM samples
that they examined. They concluded that postswitch
MM plasma cells most likely originate from a single
CSR event in a clonotypic preswitch IgM1 cell, and
that preswitch IgM1 cells do not play a direct role in
generating postswitch MM plasma cells.THE RESPONSE OF CLONOTYPIC B CELLS
TOTHERAPY
Clonotypic B cells have not been eliminated by any
of the chemotherapy regimens studied to date, and
have remained at high levels during transient remis-
sions [19,24]. Moreover, patients in the progressive
phase of disease or in relapse have significantly higher
numbers of B cells compared with patients in transient
remission and untreated patients [24]. It was observed
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change with treatment, the number of small B cells de-
creased significantly after chemotherapy compared
with that in untreated patients. This possibly could re-
flect depletion of the primarily normal polyclonal B
cell population, with the retention of treatment-resis-
tant clonotypic B cells. However, Rasmussen et al. [27]
described a case in which the number of large B cells,
but not small B cells, decreased markedly after chemo-
therapy and transplantation. These large clonotypic B
cells in the PB remained at low levels despite recur-
rence with massive involvement of the BM.
The relative unresponsiveness of blood clonotypic
B cells to therapy suggests their drug resistance. In
myeloma, the multidrug-resistance transport pump,
P-glycoprotein (P-gp), is known to be expressed at
moderate to high density on blood B cells in the major-
ity of patients [38]. In these patients, 6% to 57% of the
small B cells and 75% to 84% of large B cells express
P-gp. Only a small proportion of patients have none
or very few B cells that express detectable P-gp.
Whereas patients in temporary remission have an in-
creased proportion of P-gp1 small B cells, patients re-
sponding to therapy have a significantly reduced
proportion of P-gp1 small B cells, and many patients
lack detectable P-gp on their small B cells. P-gp expres-
sion in large blood B cells increases considerably after
chemotherapy, with the highest proportions (80%-
90%) of CD19 1 Pgp1 B cells seen in patients with
progressive disease (PD) and those in temporary remis-
sion [38]. Moreover, P-gp expressed by clonotypic B
cells seems to be functional, as demonstrated by dye ef-
flux studies [38,39].The aforementioned clinical behav-
ior and biological properties of clonotypic B cells may
confirm the hypothesis that these cells are highly che-
motherapy-resistant and responsible for disease relapse.
Because they apparently recirculate through the
organism, it seems that, at least at this stage, theirmech-
anisms of drug resistance are rather independent of BM
niche, but rely on intrinsicmechanisms.This could sug-
gest that even the novel agents targeting the BMmicro-
environment may not eradicate circulating MM
clonotypic B cells.
Despite the availability of novel therapies, auto-
SCT remains a standard of care in patients with MM
who qualify for such procedures [11]. It is based on
high-dose chemotherapy followed by stem cell rescue
using preparation of autologous PB nucleated cells en-
riched in the HSC fraction. Because the clonotypic B
cells have been shown to recirculate through blood,
it seems very likely that they are being collected during
leukapheresis and survive in stem cell products. Szcze-
pek et al. [19] first observed a high frequency of these
cells in the granulocyte colony-stimulating factor
(G-CSF)–mobilized blood used for stem cell rescue.
In a larger cohort of patients, approximately 1%-5%
of white blood cells in the apheresis products wereshown to be clonotypic, and approximately 4  107
clonotypic MM B cells per liter of apheresis product
was reinfused to patients [33]. This seems to be consis-
tent with observations of another group revealing that
the number of PB CD19 1MM cells increases in the
last days of PBSC collection [40]. In such a situation, if
the clonotypic B cells represented MM stem cell
fraction, when infused they could directly contribute
to relapse after auto-SCT. Although the clinical obser-
vation of complete remission after auto-SCT seems to
argue against this hypothesis somehow, transplanted
clonogenic B lymphocytes possibly may enter a dor-
mancy state associated with either the freezing proce-
dure or a change in the microenvironment, and finally
begin to proliferate in response to an unknown stimu-
lus. On the other hand, the relapse after auto-SCT is
thought to originate in cells that survive myeloablative
(MA) therapy, not in leukapheresis products. Several
groups [41-43] found no clinically relevant advantage
in terms of remission after auto-SCT in the case of
transplantation of isolated CD341 hematopoietic
cells over the whole white blood cell product.
Currently, allo-SCT transplantation is the only
curative treatment option for patients with MM.
This may suggest that, contrary to current chemother-
apeutic approaches, allo-SCT is able to eliminate the
MM stem cells. The MM clonotypic B cells could be
a potential target for the graft-versus-myeloma effect
directed against either specific tumor-associated
antigens or minor histocompatibility molecules.
Unfortunately, no study has investigated the expres-
sion of HLA class I and II molecules or costimulatory
molecules by these cells. Functional studies of their
immunogenicity or immunoreactivity would be of po-
tential clinical interest and application. The efficiency
of reduced-intensity conditioning (RIC) allo-SCT,
which is most commonly used in MM, is based on
the graft-versus-myeloma effect. The chemoresistance
of clonotypic B cells and the curative effect of RIC
allo-SCT seem to support this treatment option. To
confirm this, Szczepek et al. [19] described a patient
whose clonotypic B cells were only mildly depleted
by chemotherapy regimens and were still present at
allo-SCT, but whose number was reduced 28-fold at
7 months and became undetectable at 14 months post-
transplantation, suggesting their eradication by the
graft-versus-myeloma effect.ARE THEY MALIGNANT?
Based on the aforementioned studies, the role of
clonotypic B cells in the pathology ofMM remains un-
clear. Although the immunoglobulin gene sequences
of these cells suggest that they belong to the MM
clone, they also may represent the existing members
of premalignant monoclonal cell populations that
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MGUS is considered a premalignant tumor that prog-
resses toMMat a rate of 0.6% to 3%per year [45]. The
immunoglobulin heavy-chain genes of MGUS cells
typically have the exact same sequences as MM cells,
and thus cannot be used to distinguish remaining
MGUS cells, which are more likely to have a B cell
phenotype. Pilarski et al. [38] have shown by flow cyto-
metric DNA analysis that MM clonotypic B cells are
aneuploid, similar to MM plasma cells, apparently
confirming their MM nature [38]. Moreover, karyo-
typic abnormalities often are present in MGUS [45].
While the evolution of MGUS cells to MM cells is as-
sociated with the acquisition of activating mutations
(eg, K-Ras, N-Ras, and FGFR3), these molecular sig-
natures should help experimentally identity clonotypic
B cells in the future. Based on the aforementioned
studies, it seems that at least a proportion of clonotypic
B cells actually belong to the MM clone. Previous in
vivo experiments seem to confirm this hypothesis. Clo-
notypic B cells obtained from the peripheral blood of
MM patients have been observed to successfully en-
graft into immunocompromised mice. Moreover,
they have been found to differentiate into mature
MM plasma cells, to secrete monoclonal protein, and
to produce osteolytic lesions resembling human dis-
ease [33,46,47]. Indirect evidence that these cells can
self-renew in vivo comes from the finding that BM
obtained from primary recipients who developed
human-type MM successfully transferred the disease
to secondary recipients. Therefore, at least a propor-tion of clonotypic B cells seems to be capable of re-
newal of the MM mass after transient remission.MULTIPLE MYELOMA STEM CELLS
Matsui et al. [23] recently reported the results of in
vitro studies apparently confirming the existence of
so-called ‘‘MM stem cells’’ at the B lymphocyte level
of differentiation. These authors found that human
MM cell lines contain a small (\ 5%) subpopulation
that lack CD138 expression. They performed serial
replating experiments in vitro with MM cell lines and
MM cells isolated from clinical samples. CD138- cells
isolated from the cell lines were shown to undergo sig-
nificantly greater clonogenic expansion than CD1381
cells after serial replating. Similarly, CD138-MMcells
from clinical BM samples gave rise to colonies and
could be successfully replated, whereas CD1381 cells
did not. In contrast to CD1381 cells, CD138- MM
cells from human BM successfully engrafted long-
term into NOD/SCIDmice, indicating their potential
for self-renewal. CD138- MM stem cells isolated from
cell lines expressed CD19 and CD20 molecules char-
acteristic of B lymphocytes. In addition, depletion of
CD191, CD221, and CD201 cells from the popula-
tion of CD138- MM cells obtained from clinical
samples significantly decreased their clonogenic
growth. Therefore, it is reasonable to assume that
MM stem cells are CD191, CD201, CD221, and
CD138- and express clonal immunoglobulin light
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on clonotypic MM B cells. Moreover, they revealed
that the hedgehog (Hh) signaling pathway, which reg-
ulates progenitor cell fate in normal development and
homeostasis, is involved in the maintenance of CD19
1 CD138- cells isolated from MM cell lines and clin-
ical BM samples. Hh stimulation was not required by
terminally differentiated CD19-CD1381 plasma
cells, however [48]. The Hh ligand promoted expan-
sion of MM stem cells without their differentiation.
On the other hand, the Hh pathway blockade,
although having little or no effect onmalignant plasma
cell growth, markedly inhibited clonal expansion, ac-
companied by terminal differentiation of purified
MM stem cells. In contrast to MM CD1381 plasma
cells, the clonogenic MMCD138- B cells were further
revealed to be highly resistant to clinical antimyeloma
agents in vitro [49]. This is related, at least partially, to
their high drug efflux capacity and intracellular drug
detoxification activity, as shown in Hoechst efflux
and Aldefluor assays. Cells with these characteristics
have been found in the PB of MM patients as well.
Therefore, it is reasonable to assume that circulating
clonotypic B cell populations represent MM stem
cells, and that the relative resistance of such cells to
chemotherapy leads to relapse following chemother-
apy and SCT.
On the other hand, some earlier studies have sug-
gested that cells with properties of MM stem cells re-
side within malignant plasma cell fractions [50,51].
Yaccoby and Epstein [50] used a model of humanized
SCID mice (SCID-hu) with human bone implant and
sorted plasma cells based on their CD3811CD45-
phenotype from the BM and blood ofMMpatients. In-
terestingly, they showed that only plasma cells could
engraft into the human bone implant and produce
xenogenic myeloma in recipient animals. In contrast,
the remaining fractions, regardless of B lymphocyte
content, did not produce MM.Moreover, the circulat-
ing plasma cells obtained from human blood appeared
to grow more avidly in the SCID-hu hosts compared
with their bone marrow counterparts. This suggests
that these cells represent a subpopulation of the plasma
cells in the bonemarrow. Importantly, theMMplasma
cells could engraft only human bone implants, not
murine organs. They also could disseminate the dis-
ease to another implant, meaning that a fraction of
them circulated within the murine model. These re-
sults have been discussed by Matsui et al. [49], whose
reached the opposite conclusion, suggesting that the
human BM environment used in the SCID-hu model
could selectively enhance the proliferation of a more
differentiated plasma cell fraction, as it does in the
AML blast cell population. If this were the case, then
the methodology of Yaccoby and Epstein [50] would
not provide reliable data for determining the MM
stem cell phenotype.Yaccoby [51] recently reported an innovative ap-
proach to addressing the concept of MM stem cells.
He suggested that MM cells have plasticity, expressed
by the ability of terminally differentiated tumor cells to
reprogram and dedifferentiate into an immature, resil-
ient phenotype. He co-cultured CD1381MMplasma
cells with osteoclasts in vitro for 6 weeks and observed
that they changed their phenotype from CD45(low/
intermediate), CD38(high), CD138(high), CD19-,
CD34- to CD45(intermediate/high), CD19(low),
CD34(low) plasmablastic cells. Expression of CD38
and CD138 were reduced to subpopulations with
CD38(intermediate) and CD138(low) levels. Interest-
ingly, this change was not from clonal selection of rel-
evant population, because the plasma cells remained
highly viable (97%) throughout the experimental
period, but dedifferentiated and acquired a stem cell
phenotype. Yaccoby has suggested a new model for
myelomagenesis in which the MM plasma cells resid-
ing closely with osteoclasts in lytic bone lesions
acquire stem cell properties, becoming quiescent and
apoptosis-resistant. They survive conventional high-
dose chemotherapy and auto-SCT and are responsible
for disease relapse. The plasticity of these MM cells
finally changes, however, resulting in a population of
cells that have a predominantly permanent MM stem
cell phenotype and are autonomous, highly prolifera-
tive, and resistant to apoptosis.CONCLUSION
Despite the results of recent studies that claim to
identify MM stem cells with a phenotype resembling
most frequently described clonotypic MM B cells,
this hypothesis remains controversial. Because clono-
typic MM B cells have been shown to express CD20
molecules, two therapeutic clinical trials were
performed with anti-CD20 monoclonal antibody
(mAb; rituximab) [52,53]. Rituximab was expected to
suppress the cells responsible for renewal of MM pop-
ulation, thereby providing a curative effect. Unfortu-
nately, neither trial demonstrated a significant
clinical benefit to patients, despite the clearly decreas-
ing number of circulating B cells observed. In theory,
the BM environment could provide protective condi-
tions for MM stem cells, causing rituximab resistance
[10]. Some studies have clearly negated the existence
of clonotypic MM B cells [54], whereas others support
the hypothesis that plasma cells are responsible for
renewal of the tumor mass and relapse [50,51]. All of
these findings have contributed to the overall skepti-
cism in the scientific community regarding the exis-
tence of MM stem cells. Most publications on
clonotypic B cells come from the same group of au-
thors, and the existence, properties, and identity of
MM stem cells need to be confirmed by other teams.
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journals, and recent studies seem to elegantly confirm
the properties of these cells, this seems to be ignored
by most MM researchers. In our opinion, clonotypic
B cells may represent a variety of cells, some of which
have properties of MM stem cells. The remaining cells
may represent ‘‘fossils’’—members of cell clones that
finally transformed into MM cells after acquiring key
mutations. Similar observations have been made in
other neoplastic disorders, such as the transformation
of chronic myelogenous leukemia (CML) and myelo-
dysplastic syndrome (MDS) into AML. In such situa-
tions, although the new, more aggressive clone arises
and expands, cells of the underlying chronic disorder
remain; however they are usually not the subject of in-
vestigation, because the more malignant disease at-
tracts the most attention. A good example of this
situation is the transformation of CML into acute
megakaryocytic leukemia [55]. Using a targeted se-
quential fluorescein in situ hybridization (FISH) tech-
nique, Pullarkat et al. [55] detected 2 copies of the
BCR-ABL1 fusion gene in the leukemic blasts and
a single copy of BCR-ABL1 fusion gene in the
neutrophils, thereby proving the origin of the mega-
karyoblastic leukemia from a previously undiagnosed
CML clone. Importantly, this ‘‘fossil-like’’ clone still
existed after the transformation. Alternatively, the hy-
pothesis that MM plasma cells may de-differentiate
and acquire a clonotypic MM B cell phenotype is, al-
though highly controversial, very attractive, and may
link the multiple existing hypotheses. In conclusion,
investigations of MM stem cells should be of priority
to design curative, MM stem cell–directed therapies.ACKNOWLEDGMENTS
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